stars 1 stars 2 stars 3

CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.

CinnaGen Questions

The CinnaGen annual revenue was $124.1 million in 2026.

Mehran Montajabi is the Vice President of CinnaGen.

429 people are employed at CinnaGen.

CinnaGen is based in Tehran, Tehran.

The NAICS codes for CinnaGen are [541713, 54, 541, 54171, 5417].

The SIC codes for CinnaGen are [873, 87].

Top CinnaGen Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users